Biomarkers Market: Current Analysis and Forecast (2021-2027)

Biomarkers Market: Current Analysis and Forecast (2021-2027)

Biomarkers Market is expected to exceed the market valuation of more than US$ XX billion in 2027 and is expected to grow at a significant CAGR of XX% during the forecast period (2021-2027). Biological molecules found in blood, tissues or other body fluids which is a sign of normal or abnormal process or of a condition or disease. A biomarker can be used to see how well the body is responding to a treatment for a disease or condition. This is called molecular marker and signature molecule. Biomarkers are being used in clinical medicine since decades. With the rise of genomics and other advances in molecular biology, studies on biomarkers have entered a new era and hold promise for early diagnosis and effective treatment of many diseases. A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention. They can be classified into five categories based on their application in different disease stages : 1) antecedent biomarkers are used to identify the risk of developing an illness; 2) screening biomarkers, for screening of subclinical diseases; 3) diagnostic biomarkers which can recognize overt diseases; 4) staging biomarkers to categorize the severity of disease; and 5) prognostic biomarkers to predict the future disease course, including recurrence, response to therapy, and monitoring efficacy of therapy.

Biomarkers can indicate a variety of health or disease characteristics, including the level or type of exposure to an environmental exposures, markers of subclinical or clinical diseases, or indicators of response to therapy.

The major factors for this increase in the demand for diagnostic markets where conventional diagnostic tools were focused on producing accurate and consistent results. There are significant challenges in presenting accurate results in the early stages of diseases, especially in the case of cancer. Diagnostic biomarkers are minimally or non-invasive tools. Biomarkers which are integrated with key imaging and data management technologies is meeting the market expectations, however, they also have a few setbacks. Biomarkers are used in imaging technology to provide clear imaging of oncology tumors and other problems and also eliminate chance of radiation exposure during imaging through CT scan and MRI scan. Diagnostic biomarkers are non-invasive or minimally invasive tools. Biomarkers, which are integrated with key imaging and data management technologies, is meeting the market expectations, however, has setbacks too. Biomarkers are used in imaging technology to provide clear exposure during imaging through CT scan and MRI scan. Companion diagnostics and biomarkers have become increasingly relevant in the practice of medicine, which leads to improved diagnosis, monitoring and treatment across several disease areas. It can be used to identify, patients who are likely to respond well to certain drugs or treatment options. These diagnostics are often used in conjunction with a specific drug. For instance, the Oncomine Dx Target Test (Thermo Fisher Scientific, Inc.) helps in biomarker testing of non-small cell lung cancer (NSCLC) patients eligible for ROZLYTREK (entrectinib).

F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, QIAGEN N.V., PerkinElmer, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Enzo Biochem, Inc., Charles River Laboratories International, Inc., and Eurofins Scientific are some of the prominent players operating in the Biomarkers market. Several M&As along with partnerships have been undertaken by these players to facilitate customers with hi-tech and innovative products/technologies.

Insights Presented in the Report

“Amongst Product, Consumables segment holds the major share”

Based on Product, the Biomoarkers Market is segmented into Consumables, Services, and Software. Increase of consumables is because of the increase in the use of kit based products for biomarker testing and the repeated purchase of consumables. Use of biomarkers has become an integral part of both disease detection and treatment. The detection of biomarkers in pre-symptomatic patients leads to the ability to start treatment in early stages of disease, thus drastically improving outcomes.

“Amongst Type, Efficacy Biomarkers Segment holds the major share”

Based on Type, the Biomarkers Market is segmented into Safety Biomarkers, Efficacy Biomarkers, Predictive Biomarkers, Surrogate Biomarkers, Pharmacodynamics Biomarkers, Prognostic Biomarkers, and Validation Biomarkers. Efficacy biomarkers indicate clinical outcomes of patients or beneficial effect of a given treatment. For efficacy prediction, general prediction markers for certain therapy strategies (e.g. antihormone treatment in breast cancer) can be differentiated from real companion diagnostic biomarkers (CDx). CDx are co-developed with a certain drug and their application is often listed as mandatory in the drug label.

“Amongst Application, Diagnostics segment holds the major share”

Based on Application, the Biomarkers Market is segmented into Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, and Other Applications. Biomarkers are increasingly being used for the diagnosis of diseases like cancer, infectious diseases, cardiovascular disorders and neurological disorders. This is driving the growth of the diagnostics segment in the biomarkers market. For example, people with diabetes have a two to four fold increased risk of developing cardiovascular diseases, and stroke, and these complications account for 65% of mortality from diabetes.

“Amongst Disease Indication, Cancer category holds the major share”

Based on Diseases Indication, the Biomarkers Market is segmented into Cancer, Infectious Diseases, Immune Disorders, Neurological Disorders, Cardiovascular Disorders, and Other Disease Indications. Cancer category is further segmented into Solid biopsy and Liquid Biopsy. There are many potential applications of biomarkers in oncology, including differential diagnosis, risk assessment, screening, determination of prognosis, prediction of response to treatment and monitoring of progression of disease. Biomarkers play critical roles in all stages of disease, it is important that they undergo rigorous evaluation, including analytical validation, clinical validation and assessment of clinical utility, prior to incorporation into routine clinical care. With the help of these tools biomarkers can help expedite the cancer detection and intervention process, which is important as the number of cancer cases is rising globally at a significant rate.

“North America represents one of the largest markets of Biomarkers market”

For a better understanding of the market dynamics of the Biomarkers market, a detailed analysis was conducted for different regions across India including North America (US, Canada, Rest of North America), Europe (Germany, UK, France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Australia, Rest of Asia-Pacific), Rest of World. North America dominated the market and grabbed around XX% market share owing to increasing chronic diseases in the region.

Reasons to buy this report:

• The study includes market sizing and forecasting analysis validated by authenticated key industry experts
• The report presents a quick review of overall industry performance at one glance
• The report covers an in-depth analysis of prominent industry peers with a primary focus on key business financials, product portfolio, expansion strategies, and recent developments
• Detailed examination of drivers, restraints, key trends, and opportunities prevailing in the industry
• The study comprehensively covers the market across different segments
• Deep dive regional level analysis of the industry